WO2007057682A1 - A method for in vitro molecular evolution of protein function - Google Patents
A method for in vitro molecular evolution of protein function Download PDFInfo
- Publication number
- WO2007057682A1 WO2007057682A1 PCT/GB2006/004294 GB2006004294W WO2007057682A1 WO 2007057682 A1 WO2007057682 A1 WO 2007057682A1 GB 2006004294 W GB2006004294 W GB 2006004294W WO 2007057682 A1 WO2007057682 A1 WO 2007057682A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- sequence
- oligonucleotides
- parent
- polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
Definitions
- the present invention relates to a method for in vitro molecular evolution of protein function which permits control on the variability introduced into selected regions of a parent protein.
- Protein function can be modified and improved in vitro by a variety of methods, including site directed mutagenesis (Alber et al, Nature, 5; 330(6143):41-46,
- the method of random mutagenesis together with selection has been used in a number of cases to improve protein function and two different strategies exist. Firstly, randomisation of the entire gene sequence in combination with the selection of a variant (mutant) protein with desired characteristics, followed by a new round of random mutagenesis and selection. This method can then be repeated until a protein variant is found which is considered optimal (Schier R. et al, J. MoI. Biol. 1996 263 (4): 551-567).
- the traditional route to introduce mutations is by error prone PCR (Leung et al, Technique, 1: 11-15, 1989) with a mutation rate of approximately 0.7%.
- defined regions of the gene can be mutagenised with degenerate primers, which allows for mutation rates of up to 100% (Griffiths et al, EMBO. J, 13: 3245-3260, 1994; Yang et al, J. MoI. Biol. 254: 392-403, 1995).
- Random mutation has been used extensively in the field of antibody engineering.
- Antibody genes formed in vivo can be cloned in vitro (Larrick et al, Biochem. Biophys. Res. Comrnun. 160: 1250-1256, 1989) and random combinations of the genes encoding the variable heavy and light genes can be subjected to selection (Marks et al, Biotechnology, 10: 779-783, 1992). Functional antibody fragments selected by these methods can be further improved using random mutagenesis and additional rounds of selections (Schier R. et al, J. MoI. Biol. 1996 263 (4): 551- 567).
- Combinatorial pairing of genes has also been used to improve protein function, e.g. antibody affinity (Marks et al, Biotechnology, 10: 779-783, 1992).
- DNA shuffling Another known process for in vitro mutation of protein function, which is often referred to as “DNA shuffling”, utilises random fragmentation of DNA and assembly of fragments into a functional coding sequence (Stemmer, Nature 370:
- the DNA shuffling process generates diversity by recombination, combining useful mutations from individual genes. It has been used successfully for artificial evolution of different proteins, e.g. enzymes and cytokines (Chang et al. Nature Biotech. 17, 793-797, 1999; Zhang et al. Proc.
- the genes are randomly fragmented using DNase I and then reassembled by recombination with each other.
- the starting material can be either a single gene (first randomly mutated using error-prone PCR) or naturally occurring homologous sequences (so-called family shuffling).
- DNase I hydrolyses DNA preferentially at sites adjacent to pyrimidine nucleotides, therefore it is a suitable choice for random fragmentation of DNA.
- the activity is dependent on Mg or Mn ions, Mg ions restrict the fragment size to 50bp, while the Mn ions will give fragment sizes less than 50bp. Therefore, in order to have all possible sizes for recombination the gene in question needs to be treated at least twice with DNase I in the presence of either of the two different ions, followed by removal of these very same ions.
- shuffle DNA between any clones if the resulting shuffled gene is to be functional with respect to expression and activity, the clones to be shuffled have preferably to be related or even identical, with the exception of a low level of random mutations. DNA shuffling between genetically different clones will generally produce non-functional genes.
- the present invention seeks to provide improved methods for in vitro protein evolution.
- the invention aims to provide a method which permits control of the degree of variability introduced in selected regions of a parent polynucleotide sequence.
- a method for generating a variant polynucleotide molecule, or population thereof, from a parent polynucleotide molecule comprising the steps of
- step (d) wherein the degree of sequence variability in a selected region of the at least one polynucleotide molecule produced in step (d) is controlled by the addition of one or more oligonucleotides of predetermined variability, which oligonucleotides anneal to a sequence that lies between, but excludes, the 3 'and 5' terminal nucleotides of the parent polynucleotide molecule.
- a key advantage provided by the methods of the present invention is that they allow control of the degree of sequence variability introduced into the parent polynucleotide sequences, by the addition of one or more oligonucleotides of predetermined variability.
- Such oligonucleotides are able to anneal (preferably under high stringency conditions) to an internal target sequence present in one or more of the parent polynucleotide sequences.
- the oligonucleotides of predetermined variability are capable of annealing to an internal sequence that lies between, but excludes, the 3 'or 5 'terminal nucleotide of the parent polynucleotide molecule (such that the oligonucleotides are not able to anneal to the 3 'or 5 'terminal nucleotides).
- Oligonucleotides of predetermined variability' is not intended to encompass 3 'or 5 'end primer sequences or a full-length template.
- step (c) may additionally comprise adding primer sequences that anneal to the 3 'and/or 5 'ends of at least one of the parent polynucleotides under annealing conditions.
- the oligonucleotides of predetermined variability are added prior to or in step (b) and the nuclease used to digest the parent polynucleotides is specific for single-stranded polynucleotides (for example, Sl nuclease, Exo I, Exo T and Mung bean nuclease).
- the oligonucleotides When so added, the oligonucleotides anneal/hybridise to the first and second populations of single-stranded parent polynucleotides, thereby producing double-stranded regions which are thus protected from digestion from the single-strand specific nuclease (see Figure 2). Consequently, variability within this protected sequence is controlled in the resulting variant polynucleotides produced in step (d).
- the oligonucleotides of predetermined variability are added after step (b) and prior to or in step (c).
- the polynucleotide fragments produced by nuclease digestion are 'spiked' with the oligonucleotides, which are then incorporated during the re- annealing/hybridisation process into the variant polynucleotides produced in step (d) (see Figure 3).
- the first and second populations of polynucleotides are single-stranded in this embodiment.
- oligonucleotides of predetermined variability are produced using methods well known in the art, such as error-prone PCR or using an oligonucleotide synthesiser (such as those commercially-available from MWG Biotech, Ebersberg, Germany).
- oligonucleotides of predetermined variability is not essential; what is important is that the degree of variability within the oligonucleotides is known (at least in a relative sense, if not an absolute sense).
- the oligonucleotides of predetermined variability share at least
- sequence identity with the internal sequence of a parent polynucleotide sequence, for example at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
- the percent sequence identity between two polynucleotides may be 04294
- sequence identity may be analysed using the Clustal W program (Thompson et al, (1994) Nucleic Acids Res 22, 4673-80).
- the parameters used may be as follows:
- Fast pairwise alignment parameters K-tuple (word) size; 1, window size; 5, gap penalty; 3, number of top diagonals; 5. Scoring method: x percent. Multiple alignment parameters: gap open penalty; 10, gap extension penalty; 0.05. Scoring matrix: BLOSUM.
- the oligonucleotides of predetermined variability share 100% sequence identity with the internal sequence of a parent polynucleotide sequence.
- the oligonucleotides may all be of a same nucleotide sequence.
- the oligonucleotides of predetermined variability are of at least two different sequences.
- the oligonucleotides are variants of the. same internal sequence of a parent polynucleotide sequence.
- oligonucleotides of predetermined variability may be targeted to the same internal sequence or different internal sequences of the parent polynucleotides.
- the oligonucleotides of predetermined variability share 100% sequence identity with, or are variants of, at least two different regions of the parent polynucleotides.
- oligonucleotides of predetermined variability may be of any length provided that they do not constitute a full-length template.
- the oligonucleotides are between 10 and 500 nucleotides in length. More preferably, the oligonucleotides are between 50 and 200 nucleotides in length, for example about 100 nucleotides in length.
- the invention provides a method for generating variant forms of a parent polynucleotide sequence.
- the method of the invention may be carried out on any polynucleotide which encodes a polypeptide product, including any proteins having binding or catalytic properties, e.g. antibodies or parts of antibodies, enzymes or receptors.
- any polynucleotide that has a function that may be altered, such as catalytic RNA may be mutated in accordance with the present invention.
- the parent polynucleotide encoding one or more protein motif is at least 12 nucleotides in length, more preferably at least 20 nucleotides in length, even more preferably more than 50 nucleotides in length.
- Polynucleotides being at least 100 nucleotides in length or even at least 200 nucleotides in length may be used. Where parent polynucleotides are used that encode large proteins such as enzymes or antibodies, these may be many hundreds or thousands of bases in length. The present invention may be carried out on any size of parent polynucleotide.
- the altered sequence of the at least one polynucleotide molecule produced in step (d) is associated with an altered property or characteristic of the polynucleotide or polypeptide encoded thereby.
- the altered property or characteristic of a polynucleotide or polypeptide generated by the method of the invention may be any variation or alteration in the normal activity of the wild type (parent) polynucleotide or of the polypeptide, protein or protein motifs it encodes.
- the methods of the invention may be applied as follows: (i) to modulate, either positively or negatively, the catalytic activity of an enzyme;
- the methods of the invention may be used to alter a property/function of any protein, polypeptide or polynucleotide.
- Phage display has been used to clone functional binders from a variety of molecular libraries with up to 10 11 transformants in size (Griffiths et al, EMBO. J. 13: 3245-3260, 1994). Thus, phage display can be used to clone directly functional binders from molecular libraries, and can also be used to improve further the clones originally selected.
- Other types of viruses that have been used for surface expression of protein libraries and selections thereof are baculoviras (Bvidk et al Biotechnol 13:1079- 1084.
- Selection of functional proteins from molecular libraries can also be performed by cell surface display. Also here, the phenotype is directly linked to its corresponding genotype.
- Bacterial cell surface display has been used for e.g. screening of improved variants of carboxymethyl cellulase (CMCase) (Kim et al Appl Environ Microbiol 66:788-93, 2000).
- CMCase carboxymethyl cellulase
- Other cells that can be used for this purpose are yeast cells (Boder and Wittrup Nat.
- the parent polynucleotide preferably encodes one or more protein motifs. These are defined as regions or elements of polynucleotide sequence that encode a polypeptide (i.e. amino acid) sequence which has a characteristic protein function.
- a protein motif may define a portion of a whole protein, such as an epitope, a cleavage site or a catalytic site etc.
- the selected region of the parent polynucleotide molecule in which the degree of variability is controlled corresponds to (i.e. encodes) one or more such protein motifs.
- the oligonucleotides of predetermined variability may be targeted to an internal sequence of the parent polynucleotide molecule which encodes a protein motif.
- the method of the invention may be operated using, as a parent polynucleotide, any nucleic acid starting material capable of hybridising to form double-stranded complementary nucleotide sequences, for example genomic DNA (gDNA) or complementary DNA (cDNA).
- the first and second populations of polynucleotides are cDNA.
- the first and second populations of polynucleotides are single-stranded.
- first population of polynucleotides consists of plus strands of parent polynucleotide molecules and second population of polynucleotides consists of minus strands of parent polynucleotide molecules.
- first and/or second population of polynucleotides may comprise both plus and minus strands of parent polynucleotide molecules.
- the method of the invention may be used to produce variant forms of any parent polynucleotide sequence.
- the parent polynucleotide sequences are derived by mutagenesis of a single parent polynucleotide sequence, i.e. the parent polynucleotide sequences constitute variant forms of a single polynucleotide sequence.
- Random mutation of a parent polynucleotide sequence can be accomplished by any conventional method as described above, such as error-prone PCR.
- the parent polynucleotide sequences encode a ligand polypeptide.
- ligand polypeptide we include any polypeptide which interacts either in vivo or ex vivo with another biological molecule (such as another polypeptide or a polynucleotide).
- the oligonucleotides of predetermined variability share sequence identity with, or are variants of, a region of the parent polynucleotide sequences encoding an amino acid sequence which interacts, directly or indirectly, with a biological molecule, for example a binding site or modulatory site.
- the parent polynucleotide sequences encode an antibody or antibody fragment such as Fab-like molecules (Better et al (1988) Science 240, 1041); Fv molecules (Skerra et al (1988) Science 240, 1038); single- chain Fv (ScFv) molecules (Bird et al (1988) Science 242, 423; Huston et al (1988) Proc. Natl. Acad. ScL USA 85, 5879) and single domain antibodies (dAbs) (Ward et al (1989) Nature 341, 544).
- the oligonucleotides of predetermined variability preferably share sequence identity with, or are variants of, a region of the parent polynucleotide sequences encoding a complementarity- determining region (CDR).
- the oligonucleotides of predetermined variability may share sequence identity with, or be variants of, a region of the parent polynucleotide sequences encoding a framework polypeptide.
- the parent polynucleotide sequences encode an enzyme or catalytically active fragment thereof.
- enzyme any polypeptide having enzyme- like activity, i.e. a catalytic function.
- polypeptides being part of an enzyme may still possess catalytic function.
- proteins such as interferons and cytokines are included.
- the oligonucleotides of predetermined variability preferably share sequence identity with, or are variants of, a region of the parent polynucleotide sequences encoding the active site, or modulatory site (such as an allosteric regulatory site, e.g. a. cofactor binding site) or a region involved in enzyme stability (such as a protease cleavage site).
- the parent polynucleotide sequences encode an antigen.
- antigen we include antigenic peptides capable of inducing an immune response when administered, either acutely or chronically, to a mammalian host.
- the oligonucleotides of predetermined variability preferably share sequence identity with, or are variants of, a region of the parent polynucleotide sequences encoding an epitope.
- any nuclease may be used in digestion step (b) to generate polynucleotide fragments, for example exonucleases, endonucleases or restriction enzymes, or combinations thereof.
- the individual digested fragments are purified, mixed and reassembled with PCR technology.
- the assembled (reconstituted) gene may then be cloned into an expression vector for expressing the protein.
- the protein may then be analysed for altered characteristics.
- nuclease we mean a polypeptide, e.g. an enzyme or fragment thereof, having nucleolytic activity.
- nuclease is an exonuclease. More preferably, the exonucleolytic activity of the polypeptide is greater than the endonucleolytic activity of the polypeptide. More preferably, the polypeptide has exonucleolytic activity but is substantially free of endonucleolytic activity.
- Suitable exonucleases include BAL31, exonuclease I, exonuclease V, exonuclease VII, exonuclease T7 gene 6, bacteriophage lambda exonuclease and exonuclease Rec J f.
- the first and second populations of polynucleotides are digested separately in step (b).
- the size of the polynucleotide fragments may be controlled. Determining the lengths of the polynucleotide fragments in this way avoids the necessity of having to provide a further step such as purifying the fragments of desired length from a gel.
- At least one parameter of the reaction used for digestion of the first population of polynucleotide molecules is different from the equivalent parameter(s) used in the reaction for digestion of the second population of polynucleotide molecules.
- 'equivalent parameter' we mean the same parameter used in the reaction for digestion of the other population of single-stranded polynucleotide molecules.
- Suitable reaction parameters which may be varied include nuclease type, nuclease concentration, reaction volume, duration of the digestion reaction, temperature of the reaction mixture, pH of the reaction mixture, length of parent polynucleotide sequences, the amount of parent polynucleotide molecules and the buffer composition of the reaction mixture.
- a preferred embodiment of the first aspect of the invention provides a method of combining polynucleotide fragments to generate variant polynucleotide sequences, which method comprises the steps of:
- step (b) assembling a polynucleotide sequence from the sequences derived from step (a)
- oligonucleotides of predetermined variability are used to control the degree of variability in selected regions of the resultant polynucleotide sequences.
- the method further comprises the step of (c) expressing the resulting protein encoded by the assembled polynucleotide sequence and (d) screening the protein for altered properties or characteristics.
- the present invention also provides polynucleotide sequences obtained or obtainable by the method described above having an altered nucleotide sequence (preferably encoding a polypeptide having altered/desired characteristics). These polynucleotide sequences may be used for generating gene therapy vectors and replication-defective gene therapy constructs or vaccination vectors for DNA- based vaccinations. In addition, the polynucleotide sequences may be used as research tools.
- the present invention also provides a polynucleotide library of sequences generated by the method described above from which a polynucleotide may be selected which encodes a protein having the altered/desired characteristics. It is preferable that the polynucleotide library is a DNA or cDNA library.
- the present invention also provides proteins such as enzymes, antibodies, and receptors having characteristics different to that of the wild type produced by the method described above. These proteins may be used individually or within a pharmaceutically acceptable carrier as vaccines or medicaments for therapy, for example, as immunogens, antigens or otherwise in obtaining specific antibodies. They may also be used as research tools.
- the polynucleotide may be incorporated in a vector having control sequences operably linked to the polynucleotide sequence to control its expression.
- the vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted polynucleotide sequence, further polynucleotide sequences so that the protein encoded for by the polynucleotide is produced "as a fusion and/or nucleic acid encoding secretion signals so- that the protein produced in the host cell is secreted from the cell.
- the protein encoded for by the polynucleotide sequence can then be obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the protein is produced and recovering the protein from the host cells or the surrounding medium.
- Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.
- the choice of host cell can be used to control the properties of the protein expressed in those cells, e.g. controlling where the protein is deposited in the host cells or affecting properties such as its glycosylation.
- the protein encoded by the polynucleotide sequence may be expressed by methods well known in the art. Conveniently, expression may be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the protein.
- Suitable host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Also, utilising the retrovirus system for cloning and expression is a good alternative, since this virus can be used together with a number of cell types.
- Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others.
- a common, preferred bacterial host is E. coli.
- Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
- Vectors may be plasmids, viral e.g. phage, or phagemid, as appropriate.
- plasmids viral e.g. phage, or phagemid, as appropriate.
- the system can be used for the creation of DNA libraries comprising variable sequences which can be screened for the desired protein function in a number of ways. Enzyme function can be screened for with methods specific for the actual enzyme function e.g. CMCase activity, ⁇ -glucosidase activity and also thermostability. Furthermore, phage display and cell surface display may be used for screening for enzyme function (Crameri A. et al, Nature 1998 15; 391 (6664):288-291; Zhang J. H. et al, PNAS. USA 1997 94 (9): 4504-4509; Warren M.S.
- a polypeptide provided by the present invention may be used in screening for molecules which affect or modulate its activity or function. Such molecules may be useful in a therapeutic (possibly including prophylactic) context.
- the present invention also provides vectors comprising polynucleotide sequences generated by the method described above.
- compositions comprising either polynucleotide sequences, vectors comprising the polynucleotide sequences or polypeptides generated by the method described above and a pharmaceutically acceptable carrier or a carrier suitable for research purposes.
- the present invention further provides a method comprising, following the identification of the polynucleotide or polypeptide having desired characteristics by the method described above, the manufacture of that polypeptide or polynucleotide in whole or in part, optionally in conjunction with additional polypeptides or polynucleotides.
- a further aspect of the invention provides a method for making a polypeptide having altered/desired properties, the method comprising the following steps:
- step (b) expressing the variant polynucleotides produced in step (a) to produce variant polypeptides
- the invention further provides a polypeptide obtained by the above method.
- polynucleotide or polypeptide having altered/desired characteristics can then be manufactured to provide greater numbers by well-known techniques such as PCR, cloning and expression within a host cell.
- the resulting polypeptides or polynucleotides may be used in the preparation of industrial enzymes, e.g. laundry detergent enzymes where an increased activity is preferred at lower temperatures.
- the manufactured polynucleotide or polypeptide may be used as a research tool, i.e. antibodies may be used in immunoassays, and polynucleotides may be used as hybridisation probes or primers.
- the resulting polypeptides or polynucleotides may be used in the preparation of medicaments for diagnostic use, pharmaceutical use, therapy etc. as discussed as follows.
- the polypeptides or polynucleotides generated by the methods of the invention and identified as having altered characteristics can be formulated in pharmaceutical compositions.
- compositions may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
- Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included, as required.
- the invention further provides a polynucleotide or polypeptide produced by the methods of the invention for use in medicine and the use of a polynucleotide or polypeptide produced by the methods of the invention in the preparation of a medicament for use in the treatment, therapy and/or diagnosis of a disease.
- a polypeptide e.g. an antibody or fragment thereof, an enzyme
- a polynucleotide or nucleic acid molecule identified following generation by the present invention that is to be given to an individual
- administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual.
- targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibody or cell specific ligands. Targeting may be desirable for a variety of reasons; for example if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.
- these agents could be produced in the target cells by expression from an encoding gene introduced into the cells, e.g. in a viral vector (a variant of the VDEPT technique i.e. the activating agent, e.g. an enzyme, is produced in a vector by expression from encoding DNA in a viral vector).
- the vector could be targeted to the specific cells to be treated, or it could contain regulatory elements which are switched on more or less selectively by the target cells.
- the agent could be administered in a precursor form, for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated.
- ADEPT ADEPT
- VT VT
- the former involving targeting the activating agent to the cells by conjugation to a cell-specific antibody
- the latter involves producing the activating agent, e.g. an enzyme, in a vector by expression from encoding DNA in a viral vector (see for example, EP-A-415731 and WO 90/07936).
- a composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- the polynucleotide identified as having desirable characteristics following generation by the method of the present invention could be used in a method of gene therapy, to treat a patient who is unable to synthesize the active polypeptide encoded by the polynucleotide or unable to synthesize it at the normal level, thereby providing the effect provided by the corresponding wild- type protein.
- Vectors such as viral vectors have been used in the prior art to introduce polynucleotides into a wide variety of different target cells. Typically the vectors are exposed to the target cells so that transfection can take place in a sufficient proportion of the cells to provide a useful therapeutic or prophylactic effect from the expression of the desired polypeptide.
- the transfected nucleic acid may be permanently incorporated into the genome of each of the targeted tumour cells, providing long lasting effect, or alternatively the treatment may have to be repeated periodically.
- vectors both viral vectors and plasmid vectors
- a number of viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpes viruses, including HSV and EBV, and retroviruses.
- papovaviruses such as SV40
- vaccinia virus vaccinia virus
- herpes viruses including HSV and EBV
- retroviruses include retroviruses.
- Many gene therapy protocols in the prior art have used disabled murine retroviruses.
- nucleic acid into cells includes electroporation, calcium phosphate co- precipitation, mechanical techniques such as microinjection, transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.
- the aim of gene therapy using nucleic acid encoding a polypeptide, or an active portion thereof is to increase the amount of the expression product of the nucleic acid in cells in which the level of the wild-type polypeptide is absent or present only at reduced levels.
- Such treatment may be therapeutic in the treatment of cells which are already cancerous or prophylactic in the treatment of individuals known through screening to have a susceptibility allele and hence a predisposition to, for example, cancer.
- the present invention also provides a kit for generating a polynucleotide sequence or population of sequences of desired characteristics comprising reagents for ssDNA preparation, an exonuclease and components for carrying out a PCR technique, for example, thermostable DNA (nucleotides) and a stopping device, for example, EGTA.
- a kit for generating a polynucleotide sequence or population of sequences of desired characteristics comprising reagents for ssDNA preparation, an exonuclease and components for carrying out a PCR technique, for example, thermostable DNA (nucleotides) and a stopping device, for example, EGTA.
- the present invention conveniently provides for the creation of mutated enzyme gene sequences and their random combination to functional enzymes having desirable characteristics.
- the enzyme genes are mutated by error prone PCR which results in a mutation rate of approximately 0.7%.
- the resulting pool of mutated enzyme genes are then digested with an exonuclease, e.g. BAL31, and the reaction inhibited by the addition of EGTA or by heat inactivation at different time points, resulting in a set of DNA fragments of different sizes. These may then be subjected to PCR based reassembly as described above.
- the resulting reassembled DNA fragments are then cloned and a gene library constructed. Clones may then be selected from this library and sequenced.
- variable DNA sequences which can be used for further selections and analyses.
- the DNA may encode peptides where the molecules functional characteristics can be used for the design of different selection systems. Selection of recombined DNA sequences encoding peptides has previously been described (Fisch et al, PNAS. USA 1996 M 23; 93 (15): 7761-7766).
- the variable DNA population can be used to produce a population of RNA molecules with e.g. catalytic activities. Vaish et al, (PNAS.
- Figure 1 shows the general principles of in vitro molecular evolution using the FINDTM technology of Alligator Bioscience (as described in WO 02/48351).
- Figure 2 shows a preferred embodiment of the methods of the invention wherein the oligonucleotides of predetermined variability are added in step (b).
- Figure 3 shows a preferred embodiment of the methods of the invention wherein the oligonucleotides of predetermined variability are added in step (c).
- Figure 4 shows: A. Hybridisation of two different ssDNAs of different length and polarity.
- Figure 5 shows a gel image of test hybridizations:
- Lane 1 lkb DNA ladder (Invitrogen).
- Lane 2 Hybridisation of CTl 7 760bp and CTl 7 285bp in 1OmM Tris.
- Lane 3 Hybridisation of CTl 7 760bp and CTl 7 285bp in Ix PCR buffer.
- Lane 4 ssDNA CTl 7 760bp. Lane 5: ssDNA CT17 285bp.
- Figure 6 shows a gel image of Exol and ExoVII digestions:
- Lane 1 Undigested CTl 7 760bp/ CTl 7 285 hybrid in Exol buffer. Lane 2. CTl 7 760b ⁇ / CTl 7 285 hybrid digested with Exol for 10 minutes.
- Lane 4 Undigested CTl 7 760bp/ CT17 285 hybrid in ExoVII buffer.
- the methods of the present invention are shown schematically in Figures 1 to 3.
- the methods utilise the FINDTM technology of Alligator Bioscience, as described in WO 02/48351 and WO 03/097834, in the in vitro molecular evolution of one or more parent polynucleotide sequences.
- the FINDTM technology is described in WO 02/48351 and WO 03/097834.
- AmpliTaq® polymerase was purchased from Perkin-Elmer Corp., dNTPs from Boehringer Mannheim Biochemica (Mannheim, Germany), and BAL31 Nuclease from New England Biolabs Inc. (Beverly, USA). All restriction enzymes were purchased from New England Biolabs Inc. (Beverly, USA). Ethidium bromide was purchased from Bio-Rad Laboratories (Bio-Rad Laboratories, Hercules, CA, USA). T4 DNA Ligase was purchased from New England Biolabs Inc. (Beverly, USA). EDTA and EGTA were purchased from Kebo Lab (Sweden).
- AU primers were designed in the laboratory and obtained from Life Technologies (Taby, Sweden) and SGS-DNA (K ⁇ ping, Sweden).
- PCR Polymerase Chain Reactions
- an automatic thermocycler Perkin-Elmer Cetus 480, Norwalk, CT, and USA.
- PCR techniques for the amplification of nucleic acid are described in US Patent No. 4,683,195. References for the general use of PCR techniques include Mullis et al, Cold Spring Harbor Symp. Quant. Biol., 51 :263, (1987), Ehrlich (ed), PCR technology, Stockton Press, NY, 1989, Ehrlich et al, Science, 252:1643-1650, (1991), "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, Academic Press, New York, (1990).
- Agarose electrophoresis of DNA was performed with 2% agarose gels (AGAROSE (FMC Bioproducts, Rockland, ME, USA)) with 0.25 ⁇ g/ml ethidium bromide in Tris-acetate buffer (TAE-buffer 0.04M Tris-acetate, 0.00 IM EDTA).
- Samples for electrophoresis were mixed with a sterile filtrated loading buffer composed of 25% Ficoll and Bromphenolic blue and loaded into wells in a the 2% agarose gel. The electrophoresis was run at 90 V for 45 minutes unless otherwise stated in Tris-acetate buffer with 0.25 ⁇ g/ml ethidium bromide.
- the Escherichia co/z ' -strain TOPlOF' was used as a bacterial host for transformations.
- Chemically competent cells of this strain were produced basically as described Hanahan, D. 1983. Studies on transformation of Escherichia coli with plasmids. J. MoI. Biol. 166: 557-580. Electrocompetent cells of this bacterial strain were produced (Dower, WJ., J. F. Miller & CW. Ragsdale. 1988: High efficiency transformation of E.coli by high voltage electroporation. Nucleic Acids Res. 16:6127).
- the pFab5chis vector is designed to harbour any scFv gene inserted between SfLI and Notl sites (see Emgberg et al, 1995, Methods MoI.
- the SfLI site is located in the pelB leader and the Notl site is located just after the VL region, such that VH-linker-VL is inserted. In this case, an antibody directed to CD40 was used.
- Standard PCR reactions were run at 25 cycles consisting of following profile: denaturation (94 0 C, 1 minute), primer annealing (55 0 C, 1 minute) and extension (72°C, 3 minutes).
- Each PCR reaction contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 ⁇ M dNTP, 1 ⁇ M forward primer, 1 ⁇ M reverse primer, 1.25 U AmpliTaq® thermostable DNA polymerase (Perkin-Elmer Corp.), and 50 ng template in a final volume of 100 ⁇ l.
- the error prone PCR reactions were carried out in a 10 x buffer containing 500 mM NaCl, 100 mM Tris-HCl, pH 8.8, 5mM MgCl 2 100 ⁇ g gelatine (according to Kuipers et al, Nucleic Acids Res. 1991, Aug 25;19 (16):4558 but with MgCl 2 concentration increased from 2 mM to 5 mM).
- the template in pFab5chis vector was added at an amount of 50 ng. 10 ⁇ l of 10 mM MnCl 2 was added and the tube was checked that no precipitation of MnO 2 occurred. At last 5 Units of Taq enzyme was added.
- the error prone PCR was run at the following temperatures for 25 cycles without a hot start: 94°C 1 ', 45 0 C 1', 72 0 C I ' , + 72 °C for 7 minutes.
- the resulting product was an error proned (i.e. mutated) insert of 750 bp. This insert was purified with Gibco PCR purification kit, before further treatment.
- the fragment of interest was amplified by two separate PCR reactions. These reactions can be standard PCR as described above or error prone PCR also as described above.
- the primers should be designed so that in one reaction the forward primer is biotinylated and in the other reaction the reverse primer is biotinylated.
- PCR reactions with A) primers 1736 and 1635 and B) primers 1664 and 1735, with the above mentioned profile was performed for 25 cycles with pFab5chis-antibody as template. This yielded PCR-products of approximately 750 bp: in A the upper strand was biotinylated; and in B the lower strand was biotinylated.
- the non-biotinylated strands were retrieved by purification using a solid matrix coated with streptavidin e.g. Dynabeads.
- the magnetic beads are washed and equilibrated with PBS/1% BSA and B&W buffer containing 5 mM Tris pH 7.5, 1 M NaCl, and 0.5 mM EGTA. 100 ⁇ l of each PCR product is mixed with 100 ⁇ l beads dissolved in 2 x B&W buffer and incubated at room temperature for 15 minutes with rotation. Unbound PCR products are removed by careful washing twice with B&W.
- the non-biotinylated strand of the captured DNA is eluted by alkaline denaruration by letting the DNA incubate with 25 ⁇ l 0.1 M NaOH for 10 minutes in room temperature.
- the solution is separated from the beads and neutralised with 7.5 ⁇ l 0.33 M HCl and 2.5 ⁇ l 1 M Tris pH 8.
- the fragment of interest was cloned into bacteriophage M13 vectors M13mpl8 and M13mpl9 using Pstl/Hindlll restriction enzymes.
- the bacteriophage were propagated using Escherichia co //-strain TOPlOF' according to conventional methods.
- Single-stranded DNA for the upper strand was prepared from bacteriophage vector M13mpl8 and single-stranded DNA for the lower strand was prepared from bacteriophage vector M13mpl9. Briefly, 1.5 ml of an infected bacterial culture was centrifuged at 12 00Og for 5 minutes at 4 0 C. The supernatant was precipitated with 200 ⁇ l 20% PEG8000/2.5 M NaCl.
- the pelleted bacteriophage was resuspended in 100 ⁇ l TE. 50 ⁇ l phenol equilibrated with Tris- Cl (pH 8.0) was added and the sample was vortexed. After centrifugation at 12 00Og for 1 minute at RT the upper phase, containing the DNA, was transferred and precipitated with ethanol. The DNA pellet was dissolved in 50 ⁇ l TE (pH 8.0) and stored at -2O 0 C. (Sambrook et al. Molecular Cloning, A laboratory manual 2 nd edition. Cold Spring Habor Laboratory Press. 1989, chapter 4). Single-stranded DNA prepared from phage is circular and must be opened prior to BAL31 treatment. This can be performed with an endonuclease able to cleave single- stranded DNA.
- PCR products are purified using a spin column to remove excess primers from the previous PCR.
- 150 ng of the purified product is used as template in a linear amplification carried out in 100 ⁇ l of lxGeneAmp® 10 x PCR buffer containing 1.5 mM MgC12 (Applied Biosystems), 200 ⁇ M of each dNTP (New England BioLabs), 1.25 U AmpliTaq® DNA Polymerase (Applied Biosystems) and 1.0 ⁇ M of a single primer.
- PCR cycle conditions are: denaturation at 94°C for 1 minute, 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72 0 C for 1 minute followed by extension at 72 0 C for 7 minutes.
- Asymmetric PCR products are size separated from double stranded template on a 1 % agarose gel and purified using Qiaquick Gel Extraction Kit (Qiagen). Generation of single-stranded DNA using Lambda exonuclease
- a dsDNA fragment is produced using standard PCR reactions creating a DNA with unique restriction enzyme (RE) sites in the 5' and 3 '-end respectively.
- RE unique restriction enzyme
- the PCR reaction is divided in two and RE digested respectively to create a 5' phosphorylation preferentially with restriction enzymes creating 3' overhang or blunt ends.
- the digestion is performed in suitable buffer and over night to accomplish complete digestion. If an enzyme creating a 5' overhang has to be used the overhang can be filled in using a DNA polymerase.
- purification 1-4 ⁇ g dsDNA is treated with 1OU of Lambda exonuclease (eg StrandaseTM from
- the ssDNA strands (containing upper and lower strands, respectively) were subjected to separate enzymatic treatment using e.g. BAL 31 (i.e. upper strands were digested separately from lower strands).
- Each digestion reaction contained 0.02 ⁇ g/ ⁇ l ssDNA, 600 mM NaCl, 20 mM Tris-HCl, 12 mM CaCl 2 , 12 mM MgCl?, 1 mM EDTA pH 8.0 and BAL 31 at various enzyme concentrations ranging from 0.1 - 5 LVmI.
- the reactions were incubated at 30 0 C and fractions of digested ssDNA were collected sequentially at 10, 30, 60 and 120 seconds or longer.
- the reactions were stopped by addition of EDTA and heat treatment at 65 0 C for 10 minutes.
- the ssDNA fragments were purified by phenol/chloroform extraction and ethanol precipitated.
- the ssDNA are resuspended in 10 mM Tris pH 8.0.
- the digestion pattern was evaluated by 1 % agarose gel electrophoresis.
- Digested DNA fragments were purified by phenol/chloroform/isoamylalcohol extraction. 50 ⁇ l of buffered phenol was added to each tube of 100 ⁇ l sample together with 50 ⁇ l of a mixture of chloroform and isoamylalcohol (24:1). The tubes were vortexed for 30 seconds and then centrifuged for 1 minute in a microfuge at 14000 r.p.m. The upper phase was then collected and mixed with 2.5 volumes of 99.5% Ethanol (1/10 was 3M Sodium Acetate, pH 5.2). The DNA was precipitated for 1 hour in -80 0 C. The DNA was then pelleted by centrifugation for
- Reassembly of the ssDNA fragments is achieved by two sequential PCR reactions.
- the first PCR reaction should contain 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 ⁇ M dNTP, 0.3 U Taq polymerase and 2 ⁇ l BAL31 treated sample, all in a final volume of 25 ⁇ l, and subjected to 5 cycles with the following profile: 94 °C for 1 minute, 50 °C for 1 minute and 72 °C for 2 minutes + 72 0 C for 5 minutes.
- the second PCR reaction should contain 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 ⁇ M dNTP, 0.6 U Taq polymerase, 1 ⁇ M forward primer, 1 ⁇ M reverse primer, and 5 ⁇ l sample from the first PCR reaction, all in a final volume of 50 ⁇ l, and subjected to 15 cycles with the following profile: 94 °C for 1 minute, 55 0 C for 1 minute and 72 0 C for 2 minutes + 72 0 C for 7 minutes.
- the resulting products can be evaluated by agarose gel electrophoresis.
- the reassembled fragment and the plasmid pFab5chis were first cleaved with Sfil by using NEB buffer 2 including BSA and 11 U enzyme/ ⁇ g DNA. The reaction was carried out for 4 h at 5O 0 C. After this the DNA was cleaved with Notl by adding conversion buffer and 6 U enzyme/ ⁇ g DNA. This reaction was carried out for 37 0 C overnight.
- the cleavage reactions were analysed on a 1% agarose gel.
- the restriction digested insert showed a cleavage product of about 750 bp. This corresponds well with the expected size.
- the band of the cleaved insert and plasmid was cut out and gel-extracted as previously described.
- Purified cleaved pFab5chis was ligated with purified reassembled restriction digested fragment at 12°C water bath for 16 hours. 50 ⁇ l of the vector was mixed with 50 ⁇ l of the insert and 15 ⁇ l of 1Ox buffer (supplied with the enzyme), 7.5 ⁇ l ligase (5 U/ ⁇ l) and sterile water to a final volume of 150 ⁇ l. A ligation of restriction digested pFab5chis without any insert was also performed in the same manner.
- the ligation reactions were purified by phenol/chloroform extraction as described above.
- the upper phase from the extraction was collected and mixed with 2.5 volumes of 99.5% Ethanol (1/10 was 3M Sodium Acetate, pH 5.2).
- the DNA was precipitated for 1 hour in -80 0 C.
- the DNA was then pelleted by centrifugation for 30 minutes in a microfuge at 14.000 r.p.m.
- the pellet was washed once with 70% ethanol and then re-dissolved in 10 ⁇ l of sterile water.
- 5 ⁇ l of each ligation was separately mixed with 95 ⁇ l chemically competent E coli TOPlOF' incubated on ice for 1 hour and then transformed (Sambrook et al.
- test genes used here were A2.30 and A2.54 (EUmark et al. 2002 Molecular Immunology 39:349-356), two scFv clones with specificity for CD40.
- Oligonucleotides of predetermined variability corresponding to mutated forms of CDR2 of A2.30, were produced as follows.
- ssDNA was purified using the ⁇ MACS Strepatavidin kit (Miltenyi Biotec) and further purification was made on agarose gels where ssDNA was recovered using Recochips (TaKaRa). The ssDNA was precipitated with NaAc/ethanol and then redissolved in 1OmM Tris-HCl pH 8.0.
- ssDNA which served as the parent polynucleotides, was purified as described above.
- Reassembly was achieved in two stages.
- PCRl first reassembly reaction
- PCRl 7.5ng exonuclease fragmented sense and anti-sense ssDNA from A2-30 and A2-54, respectively, was mixed with 5ng CDR2 sense fragments (the latter constituting oligonucleotides of predetermined variability; see above).
- CDR2 sense fragments the latter constituting oligonucleotides of predetermined variability; see above.
- the entire reaction mixture was added to a second PCR reaction for amplification, wherein primers were added to enable the formation of full- length polynucleotides (PCR2 table 4a and 4b).
- PCR products were ligated in a pGEM-T Vector System (Promega) and sequenced.
- the overall mutation frequency was 1 mutation/1 OOObp, which corresponds to a normal frequency of mutation with standard PCR amplification (i.e. not error prone PCR).
- oligonucleotides of predetermined variability may be used to selectively increase variability within a selected region (CDR2) of a parent polynucleotide encoding an scFv molecule.
- Oligonucleotides of predetermined variability corresponding to mutated CDRl , CDR2, CDR3 and CDRl+2 ssDNA fragments, were produced as follows.
- ssDNA was purified using the ⁇ MACS Strepatavidin kit (Miltenyi Biotec). Further purification was carried out on agarose gels, from which ssDNA was recovered using Recocbips (TaKaRa).
- the ssDNA which served as the oligonucleotides of predetermined variability in the following experiment, was precipitated with NaAc/ethanol and then redissolved m 1OmM Tris-HCl pH 8.0.
- PCRl exonuclease fragmented sense and anti-sense ssDNA from A2-30 and A2-54, respectively, was mixed with oligonucleotides corresponding to mutated forms of CDRl, CDR2 and/or CDR3 (Oligonucleotides of predetermined variability'), as indicated in table 11a and 13b.
- the overall mutation frequency was 1 mutation/1 OOObp, which, corresponds to a normal frequency of mutation with standard PCR amplification ⁇ i.e. not error prone PCR).
- oligonucleotides of predetermined variability may be used to selectively increase variability within multiple selected regions (CDRl, CDR2 and CDR3) of a parent polynucleotide encoding an scFv molecule.
- PCR products are purified with JetQuick PCR purification system (Genomed). Total yield: 52.5 ⁇ g, cone: 132.6 ng/ ⁇ l
- PCR products are purified with JetQuick PCR purification system (Genomed).
- Table 18 ssDNA preparation of CTl 7 760 bp and CTl 7285 bp.
- the dsDNA was mixed with beads and applied.
- the column was washed 4 times with 100 ⁇ l I x B&W and the ssDNA was eluted with 150 ⁇ l 0.1 M NaOH (stored at -20 0 C, freshly thawed) after which 45 ⁇ l 0.33 M HCl and 15 ⁇ l 1 M Tris-HCl pH 8.0 was added to the eluate to neutralize the ssDNA.
- CTl 7 760bp and CTl 7 285b ⁇ were hybridised in a molar ratio of 1 :2.
- the sample was hybridised in a PCR machine at 95°C for 5 minutes, followed by a heteroduplex step, consisting of 45 cycles of 1 minute each where the temperature is lowered by I 0 C for each cycle. Precipitation was performed as described above and pellet dissolved in 40 ⁇ l 1OmM Tris, pH 8.
- Exol and hybridized DNA was added to the 37 0 C pre warmed water/buffer mixture.
- 17.5 ⁇ l was removed at lOmin and 15min, respectively, and heat inactivated for 10 minutes at 96°C.
- sample 2 the entire volume was removed and heat inactivated for 10 minutes at 96 0 C after 15min.
- the entire control reaction (60ng) and 2.8 ⁇ l (60ng) from 10 min and 15 min were run on an 1.2% agarose gel.
- the hybridized DNA is added.
- sample 1 17.5 ⁇ l is taken out at 20 min and 30 min, respectively, and heat inactivated for 10 minutes at 96 0 C.
- sample 2 the entire volume is taken out at 30 min and heat inactivated for 10 minutes at 96°C.
- CT17 760bp and CT17 285bp were hybridised in IxPCR buffer with molar ration 1:5 and then digested with Exol and ExoVII in two separate reactions (see Material and methods).
- test hybridisation of the two fragments clearly shows that hybridisation occurs in the sample that has been hybridised in PCR buffer, where we see a band corresponding to the hybrid, with one region of dsDNA and an overhang of ssDNA on either side. This band is smaller than the expected size, 760bp, but this is probably due to altered migration properties conferred by the ssDNA overhangs. ssDNA migrates differently from dsDNA in an agarose gel, often migrating at about half the size of the corresponding dsDNA.
- Exo I which only digests from 3' ⁇ 5', leaves a band where the ssDNA overhang on the 5'end is still present but is removed on the 3 'end. This band is again smaller than the expected size (558bp) but the ssDNA overhang on the 5'end probably alters the mobility pattern in the gel.
- ExoVII which digests from both 5'— >3' and 3' ⁇ 5,' removes all overhanging ssDNA and leaves only a dsDNA band of 285 bp.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006314310A AU2006314310B2 (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
JP2008540691A JP5349051B2 (en) | 2005-11-19 | 2006-11-17 | Methods of in vitro molecular evolution of protein function |
AT06808581T ATE516351T1 (en) | 2005-11-19 | 2006-11-17 | METHOD FOR THE MOLECULAR EVOLUTION OF PROTEIN FUNCTION IN VITRO |
ES06808581T ES2395249T3 (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
CN2006800501278A CN101351553B (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
US12/094,066 US20090203572A1 (en) | 2005-11-19 | 2006-11-17 | Method for in Vitro Molecular Evolution of Protein Function |
DK06808581.0T DK1948794T3 (en) | 2005-11-19 | 2006-11-17 | Process for molecular evolution in vitro of protein function |
CA2630183A CA2630183C (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
EP06808581A EP1948794B1 (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523582A GB2432366B (en) | 2005-11-19 | 2005-11-19 | A method for in vitro molecular evolution of protein function |
GB0523582.5 | 2005-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007057682A1 true WO2007057682A1 (en) | 2007-05-24 |
Family
ID=35580344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/004294 WO2007057682A1 (en) | 2005-11-19 | 2006-11-17 | A method for in vitro molecular evolution of protein function |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090203572A1 (en) |
EP (1) | EP1948794B1 (en) |
JP (1) | JP5349051B2 (en) |
CN (1) | CN101351553B (en) |
AT (1) | ATE516351T1 (en) |
AU (1) | AU2006314310B2 (en) |
CA (1) | CA2630183C (en) |
DK (1) | DK1948794T3 (en) |
ES (1) | ES2395249T3 (en) |
GB (1) | GB2432366B (en) |
PT (1) | PT1948794E (en) |
WO (1) | WO2007057682A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010112840A1 (en) * | 2009-03-31 | 2010-10-07 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
US8071289B2 (en) | 2000-12-22 | 2011-12-06 | Alligator Bioscience Ab | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
US8173774B2 (en) | 2006-04-20 | 2012-05-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
WO2012063084A1 (en) | 2010-11-11 | 2012-05-18 | Imperial Innovations Limited | Bacterial methods |
US8303945B2 (en) | 2007-05-01 | 2012-11-06 | Alligator Bioscience Ab | Mutants of interleukin-1 receptor antagonist |
US8552149B2 (en) | 2009-01-08 | 2013-10-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
WO2014207064A1 (en) | 2013-06-27 | 2014-12-31 | Alligator Bioscience Ab | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 |
US9834589B2 (en) | 2013-06-27 | 2017-12-05 | Alligator Bioscience Ab | CD86 variants with improved affinity for CTLA-4 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032845A1 (en) * | 1997-01-24 | 1998-07-30 | Bioinvent International Ab | A method for in vitro molecular evolution of protein function |
WO2003097834A2 (en) * | 2002-05-17 | 2003-11-27 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3546806C2 (en) * | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US4994368A (en) * | 1987-07-23 | 1991-02-19 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
US5023171A (en) * | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
DE69112207T2 (en) * | 1990-04-05 | 1996-03-28 | Roberto Crea | "WALK-THROUGH" MUTAGENESIS. |
US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
US5512463A (en) * | 1991-04-26 | 1996-04-30 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction library mutagenesis |
US5514568A (en) * | 1991-04-26 | 1996-05-07 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction |
US5858657A (en) * | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
US5733753A (en) * | 1992-12-22 | 1998-03-31 | Novo Nordisk A/S | Amplification of genomic DNA by site specific integration of a selectable marker construct |
US5514555A (en) * | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US5491074A (en) * | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
SE9304060D0 (en) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Methods to select specific bacteriophages |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5928905A (en) * | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
US6406855B1 (en) * | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6395547B1 (en) * | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5830696A (en) * | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
US6171820B1 (en) * | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US5939250A (en) * | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
US5965408A (en) * | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6368798B1 (en) * | 1995-12-07 | 2002-04-09 | Diversa Corporation | Screening for novel bioactivities |
US6238884B1 (en) * | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US6358709B1 (en) * | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
US6352842B1 (en) * | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6361974B1 (en) * | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6096548A (en) * | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US5877001A (en) * | 1996-06-17 | 1999-03-02 | Diverso Corporation | Amidase |
US5763239A (en) * | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
US5925544A (en) * | 1996-11-18 | 1999-07-20 | Novo Nordisk A/S | Method of homologous recombination followed by in vivo selection of DNA amplification |
DE69835360T2 (en) * | 1997-01-17 | 2007-08-16 | Maxygen, Inc., Redwood City | EVOLUTION Prokaryotic FULL CELLS THROUGH RECURSIVE SEQUENCE RECOMBINATION |
US6326204B1 (en) * | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6265201B1 (en) * | 1997-01-17 | 2001-07-24 | Regents Of The University Of Minnesota | DNA molecules and protein displaying improved triazine compound degrading ability |
US6291165B1 (en) * | 1997-03-18 | 2001-09-18 | Novo Nordisk A/S | Shuffling of heterologous DNA sequences |
US6159688A (en) * | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
GB9712512D0 (en) * | 1997-06-16 | 1997-08-20 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US6399383B1 (en) * | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
US20010006950A1 (en) * | 1998-02-11 | 2001-07-05 | Juha Punnonen | Genetic vaccine vector engineering |
US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
US6337186B1 (en) * | 1998-06-17 | 2002-01-08 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
US6365408B1 (en) * | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
DK1095059T3 (en) * | 1998-07-10 | 2006-10-02 | Alligator Bioscience Ab Publ | Chemotaxia inhibitory protein of staphylococcus (chips) and its use |
US20020059659A1 (en) * | 1998-08-12 | 2002-05-16 | Maxygen, Inc. | DNA shuffling to produce herbicide selective crops |
EP1105510A2 (en) * | 1998-08-12 | 2001-06-13 | Maxygen, Inc. | Dna shuffling to produce herbicide selective crops |
US6358712B1 (en) * | 1999-01-05 | 2002-03-19 | Trustee Of Boston University | Ordered gene assembly |
US6436675B1 (en) * | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
US6376246B1 (en) * | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6368861B1 (en) * | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
CA2364997A1 (en) * | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Encryption of traits using split gene sequences |
JP3722194B2 (en) * | 1999-05-20 | 2005-11-30 | セイコーエプソン株式会社 | Image display system |
US6251604B1 (en) * | 1999-08-13 | 2001-06-26 | Genopsys, Inc. | Random mutagenesis and amplification of nucleic acid |
EP1118663A1 (en) * | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Nucleic acids encoding chemotaxis inhibitory polypeptides |
AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
FR2813314B1 (en) * | 2000-08-25 | 2004-05-07 | Biomethodes | MASSIVE DIRECTED MUTAGENESIS PROCESS |
US6582914B1 (en) * | 2000-10-26 | 2003-06-24 | Genencor International, Inc. | Method for generating a library of oligonucleotides comprising a controlled distribution of mutations |
AU2002234572B2 (en) * | 2000-12-12 | 2006-07-06 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) * | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
US20030036641A1 (en) * | 2001-01-31 | 2003-02-20 | Padgett Hal S. | Methods for homology-driven reassembly of nucleic acid sequences |
US20030129709A1 (en) * | 2001-11-02 | 2003-07-10 | Olga Makarova | Method for site-directed mutagenesis of nucleic acid molecules using a single primer |
IL162811A0 (en) * | 2002-02-26 | 2005-11-20 | Du Pont | Method for the recombination of genetic elements |
-
2005
- 2005-11-19 GB GB0523582A patent/GB2432366B/en active Active
-
2006
- 2006-11-17 AU AU2006314310A patent/AU2006314310B2/en not_active Ceased
- 2006-11-17 DK DK06808581.0T patent/DK1948794T3/en active
- 2006-11-17 PT PT06808581T patent/PT1948794E/en unknown
- 2006-11-17 AT AT06808581T patent/ATE516351T1/en active
- 2006-11-17 CA CA2630183A patent/CA2630183C/en not_active Expired - Fee Related
- 2006-11-17 US US12/094,066 patent/US20090203572A1/en not_active Abandoned
- 2006-11-17 ES ES06808581T patent/ES2395249T3/en active Active
- 2006-11-17 EP EP06808581A patent/EP1948794B1/en not_active Not-in-force
- 2006-11-17 WO PCT/GB2006/004294 patent/WO2007057682A1/en active Application Filing
- 2006-11-17 CN CN2006800501278A patent/CN101351553B/en not_active Expired - Fee Related
- 2006-11-17 JP JP2008540691A patent/JP5349051B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032845A1 (en) * | 1997-01-24 | 1998-07-30 | Bioinvent International Ab | A method for in vitro molecular evolution of protein function |
WO2003097834A2 (en) * | 2002-05-17 | 2003-11-27 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071289B2 (en) | 2000-12-22 | 2011-12-06 | Alligator Bioscience Ab | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
US8173774B2 (en) | 2006-04-20 | 2012-05-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
US8303945B2 (en) | 2007-05-01 | 2012-11-06 | Alligator Bioscience Ab | Mutants of interleukin-1 receptor antagonist |
US9163072B2 (en) | 2007-05-01 | 2015-10-20 | Alligator Bioscience Ab | Mutants of interleukin-1 receptor antagonist |
US8552149B2 (en) | 2009-01-08 | 2013-10-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
WO2010112840A1 (en) * | 2009-03-31 | 2010-10-07 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
CN102428182A (en) * | 2009-03-31 | 2012-04-25 | 鳄鱼生物科学公司 | A method for in vitro molecular evolution of protein function |
CN102428182B (en) * | 2009-03-31 | 2014-12-24 | 鳄鱼生物科学公司 | A method for in vitro molecular evolution of protein function |
WO2012063084A1 (en) | 2010-11-11 | 2012-05-18 | Imperial Innovations Limited | Bacterial methods |
WO2014207064A1 (en) | 2013-06-27 | 2014-12-31 | Alligator Bioscience Ab | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 |
US9834589B2 (en) | 2013-06-27 | 2017-12-05 | Alligator Bioscience Ab | CD86 variants with improved affinity for CTLA-4 |
Also Published As
Publication number | Publication date |
---|---|
ES2395249T3 (en) | 2013-02-11 |
GB2432366B (en) | 2007-11-21 |
DK1948794T3 (en) | 2011-10-24 |
GB0523582D0 (en) | 2005-12-28 |
AU2006314310A1 (en) | 2007-05-24 |
CN101351553A (en) | 2009-01-21 |
EP1948794A1 (en) | 2008-07-30 |
GB2432366A (en) | 2007-05-23 |
AU2006314310B2 (en) | 2012-04-26 |
CA2630183C (en) | 2014-07-15 |
ATE516351T1 (en) | 2011-07-15 |
CN101351553B (en) | 2012-09-05 |
EP1948794B1 (en) | 2011-07-13 |
JP5349051B2 (en) | 2013-11-20 |
JP2009515546A (en) | 2009-04-16 |
PT1948794E (en) | 2011-09-12 |
US20090203572A1 (en) | 2009-08-13 |
CA2630183A1 (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU745150B2 (en) | A method for in vitro molecular evolution of protein function | |
US7816085B2 (en) | Method for in vitro molecular evolution of protein function | |
EP1948794B1 (en) | A method for in vitro molecular evolution of protein function | |
EP1504098B2 (en) | A method for in vitro molecular evolution of protein function | |
EP1341909B2 (en) | A method for in vitro molecular evolution of protein function | |
AU2002234572A1 (en) | A method for in vitro molecular evolution of protein function | |
US20030148353A1 (en) | Method for in vitro molecular evolution of protein function | |
GB2370038A (en) | A method for in vitro molecular evolution of protein function | |
AU777754B2 (en) | A method for in vitro molecular evolution of protein function | |
GB2388604A (en) | Molecular evolution in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680050127.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006808581 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006314310 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2008540691 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12094066 Country of ref document: US Ref document number: 2630183 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4644/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006314310 Country of ref document: AU Date of ref document: 20061117 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006314310 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006808581 Country of ref document: EP |